SCHEMBL2215019

SCHEMBL2215019

CCC(=O)[N]c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.46
NOS1 P29475 2/20 0.46
NOS2 P35228 2/20 0.46
ADRA2A P08913 3/20 0.44
ADRA2B P18089 3/20 0.44
ADRA2C P18825 3/20 0.44
PLAU P00749 1/20 0.44
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 1/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
LMNA P02545 1/20 0.38
NAPRT Q6XQN6 1/20 0.38
P4HTM Q9NXG6 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 2/20 0.38
NPC1 O15118 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5970257 0.80 ADRA2A (0.43) ADRA2AADRA2BADRA2CPLAUALDH1A1
SCHEMBL2485313 0.79 LMNA (0.50) NOS3NOS1NOS2ADRA2AADRA2B
SCHEMBL10841156 0.79 ALDH1A1 (0.50) NOS3NOS1NOS2ADRA2AADRA2B
SCHEMBL2276925 0.77 LMNA (0.48) NOS3NOS1NOS2ADRA2AADRA2B
SCHEMBL1851528 0.76 ADRA2A (0.50) NOS3NOS1NOS2ADRA2AADRA2B
SCHEMBL206947 0.75 ADRA2A (0.59) NOS3NOS1NOS2ADRA2AADRA2B
SCHEMBL3536341 0.74 ADRA2A (0.44) NOS3NOS1NOS2ADRA2AADRA2B
SCHEMBL10841472 0.72 KMT2A (0.48) ADRA2AADRA2BADRA2CPLAUMAOA
SCHEMBL6379746 0.72 NOS3 (0.44) NOS3NOS1NOS2ADRA2AADRA2B
SCHEMBL2592 0.70 CES2 (0.43) NOS3NOS1NOS2ALDH1A1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389616-B1 3,4-Dihalobenzylpiperidine derivatives and their medical use MITSUBISHI TANABE PHARMA CORP (JP) 2011-07-27 EP disclosed
US-7115635-B2 Benzylpiperidine compound MITSUBISHI PHARMA CORPORATION (JP) 2006-10-03 US disclosed
US-20040158071-A1 Chemokine inhibitors and stability in blood MITSUBISHI PHARMA CORPORATION (JP) 2004-08-12 US disclosed
EP-1389616-A1 NOVEL BENZYLPIPERIDINE COMPOUND Mitsubishi Pharma Corporation (JP) 2004-02-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158071-A1 Chemokine inhibitors and stability in blood CCL2, CXCR1, CCR5 NOS3 1554/4885NOS1 825/4885NOS2 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.